{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"28","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Amount of time following daratumumab administration until \\>25% increase in serum IgM","dispersionType":"Full Range","groups":[{"description":"* Daratumumab will be administered in three phases: Induction, consolidation and maintenance\n* During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day\n* During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle\n* During maintenance, daratumumab will be administered on day 1 of each 28-day cycle\n\nDaratumumab: Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories","id":"OG000","title":"Daratumumab"}],"paramType":"MEDIAN","populationDescription":"Only those participants who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}